Emerging experience with meningococcal serogroup B protein vaccines

Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing

Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,403 · see citing works

Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58

Tettelin, H., Saunders, N. J. S. G., Heidelberg, J. F., Jeffries, A. C., Nelson, K. E., Eisen, J. A., Ketchum, K. A., Hood, D. W., Peden, J. F., Dodson, R. J., et al. (2000) · Science · doi:10.1126/science.287.5459.1809 · Cited by 1,084 · see citing works

HUMAN IMMUNITY TO THE MENINGOCOCCUS

Goldschneider, I., Gotschlich, E. C., & Artenstein, M. S. (1969) · The Journal of Experimental Medicine · doi:10.1084/jem.129.6.1327 · Cited by 999 · see citing works

ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS

Finne, J., Leinonen, M., & Mäkelä, P. H. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90340-9 · Cited by 798 · see citing works

Global epidemiology of meningococcal disease

Harrison, L. H., Trotter, C. L., & Ramsay, M. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.063 · Cited by 753 · see citing works

A universal vaccine for serogroup B meningococcus

Giuliani, M. M., Adu‐Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A., Capecchi, B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603940103 · Cited by 733 · see citing works

Meningococcal carriage by age: a systematic review and meta-analysis

Christensen, H., May, M., Bowen, L., Hickman, M., & Trotter, C. L. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70251-6 · Cited by 650 · see citing works

Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Sierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R., & Terry, M. H. (1991) · PubMed · Cited by 512 · see citing works

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483 · see citing works

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens

Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 405 · see citing works

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

Holst, J., Martin, D., Arnold, R., Huergo, C. C., Oster, P., O’Hallahan, J., & Rosenqvist, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.071 · Cited by 404 · see citing works

Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870

Masignani, V., Comanducci, M., Giuliani, M. M., Bambini, S., Adu‐Bobie, J., Aricò, B., Brunelli, B., Pieri, A., Santini, L., Savino, S., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021911 · Cited by 395 · see citing works

Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines

Tappero, J. W., Lagos, R., Ballesteros, A. M., Plikaytis, B., Williams, D. B., Dykes, J. K., Gheesling, L. L., Carlone, G. M., Høiby, E. A., Holst, J., et al. (1999) · JAMA · doi:10.1001/jama.281.16.1520 · Cited by 368 · see citing works

Changes in <i>Neisseria meningitidis</i> Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

Cohn, A. C., MacNeil, J. R., Harrison, L. H., Hatcher, C., Theodore, J., Schmidt, M., Pondo, T., Arnold, K. E., Baumbach, J., Bennett, N., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649209 · Cited by 345 · see citing works

Vaccine Potential of theNeisseria meningitidis2086 Lipoprotein

Fletcher, L. D., Bernfield, L., Barniak, V. L., Farley, J. E., Howell, A. P., Knauf, M., Ooi, P., Smith, R. P., Weise, P., Wetherell, M., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.4.2088-2100.2004 · Cited by 331 · see citing works

Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England

Andrews, N. J., Borrow, R., & Miller, E. J. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.5.780-786.2003 · Cited by 323 · see citing works

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

Borrow, R., Andrews, N. J., Goldblatt, D., & Miller, E. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1568-1573.2001 · Cited by 317 · see citing works

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

Schneider, M. C., Prosser, B. E., Caesar, J. J. E., Kugelberg, E., Li, S., Zhang, Q., Quoraishi, S., Lovett, J. E., Deane, J. E., Sim, R. B., et al. (2009) · Nature · doi:10.1038/nature07769 · Cited by 314 · see citing works

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

Donnelly, J., Medini, D., Boccadifuoco, G., Biolchi, A., Ward, J. I., Frasch, C. E., Moxon, E. R., Stella, M., Comanducci, M., Bambini, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013758107 · Cited by 296 · see citing works

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

Gossger, N., Snape, M. D., Yu, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.85 · Cited by 285 · see citing works

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

Vogel, U. F., Taha, M., Vázquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 283 · see citing works

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Read, R. C., Baxter, D. N., Chadwick, D., Faust, S. N., Finn, A. H. R., Gordon, S. B., Heath, P. T., Lewis, D. J., Pollard, A. J., Turner, D. P. J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60842-4 · Cited by 282 · see citing works

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

Vesikari, T., Esposito, S., Prymula, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61961-8 · Cited by 279 · see citing works

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

Parikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31921-3 · Cited by 275 · see citing works

MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strain

Oster, P., LENNON, D. R., O’Hallahan, J., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.063 · Cited by 273 · see citing works

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile

Boslego, J. W. (1995) · Vaccine · doi:10.1016/0264-410x(94)00037-n · Cited by 267 · see citing works

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

Santolaya, M. E., O’Ryan, M. L., Valenzuela, M. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61713-3 · Cited by 262 · see citing works

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

Findlow, J., Borrow, R., Snape, M. D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/656741 · Cited by 257 · see citing works

Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Fredriksen, J. H., Rosenqvist, E., Wedege, E., Bryn, K., BJUNE, G., Frøholm, L. O., Lindbak, A.-K., Møgster, B., Namork, E., & Rye, U. (1991) · PubMed · Cited by 242 · see citing works

Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells

Capecchi, B., Adu‐Bobie, J., Marcello, F. D., Ciucchi, L., Masignani, V., Taddei, A., Rappuoli, R., Pizza, M., & Aricò, B. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04423.x · Cited by 232 · see citing works

Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015

MacNeil, J. R., Rubin, L. G., Folaranmi, T. A., et al. (2015) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6441a3 · Cited by 226 · see citing works

Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales

Ladhani, S. N., Beebeejaun, K., Lucidarme, J., Campbell, H. J., Gray, S. J., Kaczmarski, E., Ramsay, M. E., & Borrow, R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu881 · Cited by 208 · see citing works

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

Serruto, D., Spadafina, T., Ciucchi, L., Lewis, L. A., Ram, S., Tontini, M., Santini, L., Biolchi, A., Seib, K. L., Giuliani, M. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915162107 · Cited by 207 · see citing works

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Folaranmi, T. A., Rubin, L. G., Martin, S. W., et al. (2015) · PubMed · Cited by 203 · see citing works

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

Jiang, H.-Q., Hoiseth, S. K., Harris, S. L., McNeil, L. K., Zhu, D., Tan, C., Scott, A. A., Alexander, K., Mason, K. W., Miller, L. L., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.083 · Cited by 198 · see citing works

Neisseria meningitidis group B correlates of protection and assay standardization—International Meeting Report Emory University, Atlanta, Georgia, United States, 16–17 March 2005

Borrow, R., Carlone, G. M., Rosenstein, N. E., Blake, M., Feavers, I. M., Martin, D., Zollinger, W. D., Robbins, J., Aaberge, I. S., Granoff, D. M., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.091 · Cited by 197 · see citing works

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

Murphy, E., Andrew, L., Lee, K., Dilts, D. A., Nuñez, L., Fink, P. S., Ambrose, K. D., Borrow, R., Findlow, J., Taha, M., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600141 · Cited by 196 · see citing works

Distribution of Surface Protein Variants among Hyperinvasive Meningococci: Implications for Vaccine Design

Urwin, R., Russell, J. E., Thompson, E. A. L., Holmes, E. C., Feavers, I. M., & Maiden, M. C. J. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.5955-5962.2004 · Cited by 190 · see citing works

Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life

Snape, M. D., Dawson, T., Oster, P., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f59f6d · Cited by 187 · see citing works

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

O’Ryan, M., Stoddard, J. J., Toneatto, D., et al. (2013) · Drugs · doi:10.1007/s40265-013-0155-7 · Cited by 172 · see citing works

Two years into reverse vaccinology

Adu‐Bobie, J. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00566-2 · Cited by 150 · see citing works

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

Frosi, G., Biolchi, A., Sapio, M. L., Rigat, F., Gilchrist, S., Lucidarme, J., Findlow, J., Borrow, R., Pizza, M., Giuliani, M. M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.006 · Cited by 137 · see citing works

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression

Keiser, P. B., Biggs-Cicatelli, S., Moran, E. E., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.039 · Cited by 136 · see citing works

The epidemiology of meningococcal disease and the impact of vaccines

Khatami, A., & Pollard, A. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.3 · Cited by 135 · see citing works

A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination

Beernink, P. T., Shaughnessy, J., Braga, E. M., Liu, Q., Rice, P. A., Ram, S., & Granoff, D. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003470 · Cited by 133 · see citing works

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

Richmond, P., Marshall, H. S., Nissen, M. D., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70087-7 · Cited by 132 · see citing works

NadA Diversity and Carriage in Neisseria meningitidis

Comanducci, M., Bambini, S., Caugant, D. A., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.7.4217-4223.2004 · Cited by 132 · see citing works

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

Snape, M. D., Klinger, C. L., Daniels, E. D., John, T. M., Layton, H., Rollinson, L., Pestridge, S., Dymond, S., Galiza, E. P., Tansey, S. P., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181faa6be · Cited by 126 · see citing works

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

McNeil, L. K., Zagursky, R. J., Lin, S. L., Murphy, E., Zlotnick, G. W., Hoiseth, S. K., Jansen, K. U., & Anderson, A. S. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00056-12 · Cited by 115 · see citing works

First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak

McNamara, L. A., Shumate, A. M., Johnsen, P., MacNeil, J. R., Patel, M., Bhavsar, T. R., Cohn, A. C., Dinitz-Sklar, J., Duffy, J., Finnie, J., et al. (2015) · PEDIATRICS · doi:10.1542/peds.2014-4015 · Cited by 111 · see citing works

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

Wang, X., Cohn, A. C., Comanducci, M., Andrew, L., Zhao, X., MacNeil, J. R., Schmink, S. E., Muzzi, A., Bambini, S., Rappuoli, R., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.092 · Cited by 110 · see citing works

Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine Antigen

Welsch, J. A., Ram, S., Koeberling, O., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/528994 · Cited by 109 · see citing works

From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak

Caron, F., du Châtelet, I. P., Leroy, J., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70027-5 · Cited by 108 · see citing works

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine

Medini, D., Stella, M., & Wassil, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.015 · Cited by 105 · see citing works

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Hong, E., Giuliani, M. M., Deghmane, A., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.022 · Cited by 105 · see citing works

Enter B and W: two new meningococcal vaccine programmes launched

Ladhani, S. N., Ramsay, M. E., Borrow, R., Riordan, A. I., Watson, J. M., & Pollard, A. J. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308928 · Cited by 103 · see citing works

Effectiveness of Meningococcal B Vaccine against Endemic HypervirulentNeisseriameningitidisW Strain, England

Ladhani, S. N., Giuliani, M. M., Biolchi, A., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2202.150369 · Cited by 100 · see citing works

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

Prymula, R., Esposito, S., Zuccotti, G., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28666 · Cited by 99 · see citing works

Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015

Campbell, H. J., Saliba, V., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2015) · Eurosurveillance · doi:10.2807/1560-7917.es2015.20.28.21188 · Cited by 96 · see citing works

Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein

Lucidarme, J., Tan, L., Exley, R. M., Findlow, J., Borrow, R., & Tang, C. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00055-11 · Cited by 94 · see citing works

Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College—Rhode Island, 2015–2016

Soeters, H. M., Whaley, M. J., Alexander-Scott, N. E., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix091 · Cited by 94 · see citing works

The Discovery and Development of a Novel Vaccine to Protect against Neisseria meningitidis Serogroup B Disease

Zlotnick, G. W., Jones, T. R., Liberator, P., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34293 · Cited by 91 · see citing works

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

Giuliani, M. M., Biolchi, A., Serruto, D., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.014 · Cited by 91 · see citing works

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)

Bettinger, J. A., Scheifele, D. W., Halperin, S. A., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.063 · Cited by 90 · see citing works

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

Pajón, R., Beernink, P. T., Harrison, L. H., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.12.027 · Cited by 88 · see citing works

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

Snape, M. D., Saroey, P., John, T. M., Robinson, H., Kelly, S., Gossger, N., Yu, L., Wang, H., Toneatto, D., Dull, P. M., et al. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130257 · Cited by 85 · see citing works

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

Marshall, H. S., Richmond, P., Nissen, M. D., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.021 · Cited by 82 · see citing works

Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

Santolaya, M. E., O’Ryan, M., Valenzuela, M. T., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25505 · Cited by 82 · see citing works

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM 197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

KIMURA, A. E., Toneatto, D., Kleinschmidt, A., Wang, H., & Dull, P. M. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00304-10 · Cited by 82 · see citing works

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

Oster, P., O’Hallahan, J., Aaberge, I. S., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.023 · Cited by 81 · see citing works

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

Toneatto, D., Ismaili, S., Ypma, E., et al. (2011) · Human Vaccines · doi:10.4161/hv.7.6.15482 · Cited by 81 · see citing works

Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America

Abad, R., López, E. L., Debbag, R., et al. (2014) · Epidemiology and Infection · doi:10.1017/s0950268814001149 · Cited by 78 · see citing works

Variation of the factor H-binding protein of Neisseria meningitidis

Brehony, C., Wilson, D. J., & Maiden, M. C. J. (2009) · Microbiology · doi:10.1099/mic.0.027995-0 · Cited by 77 · see citing works

Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined

Biagini, M., Spinsanti, M., Angelis, G. D., Tomei, S., Ferlenghi, I., Scarselli, M., Rigat, F., Messuti, N., Biolchi, A., Muzzi, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521142113 · Cited by 73 · see citing works

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

Basta, N. E., Mahmoud, A. A. F., Wolfson, J. A., Ploß, A., Heller, B. L., Hanna, S., Johnsen, P., Izzo, R., Grenfell, B. T., Findlow, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514866 · Cited by 73 · see citing works

Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen

Seib, K. L., Scarselli, M., Comanducci, M., Toneatto, D., & Masignani, V. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1016915 · Cited by 71 · see citing works

Routinely vaccinating adolescents against meningococcus: targeting transmission & disease

Vetter, V., Baxter, R. P., Denizer, G., Sáfadi, M. A. P., Silfverdal, S., Vyse, A., & Borrow, R. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1130628 · Cited by 71 · see citing works

Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies

Seib, K. L., Brunelli, B., Brogioni, B., Palumbo, E., Bambini, S., Muzzi, A., Marcello, F. D., Marchi, S., ENDE, A. V. D., Aricò, B., et al. (2010) · Infection and Immunity · doi:10.1128/iai.00891-10 · Cited by 70 · see citing works

Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease

Watson, P. S., & Turner, D. P. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.057 · Cited by 68 · see citing works

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

Vu, D. M., Wong, T. T., & Granoff, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.075 · Cited by 67 · see citing works

The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme – New challenges for public health

Ladhani, S. N., Campbell, H., Parikh, S. R., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.035 · Cited by 66 · see citing works

Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding

Giuntini, S., Reason, D. C., & Granoff, D. M. (2011) · Infection and Immunity · doi:10.1128/iai.05182-11 · Cited by 65 · see citing works

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)

Koeberling, O., Ispasanie, E., Hauser, J., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.068 · Cited by 64 · see citing works

Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013

Bröker, M., Emonet, S., Fazio, C., Jacobsson, S., Koliou, M., Kuusi, M., Pace, D., Paragi, M., Pysik, A., Simões, M. J., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1051276 · Cited by 63 · see citing works

Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines

Plikaytis, B. D., Stella, M., Boccadifuoco, G., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00202-12 · Cited by 63 · see citing works

Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months

Marshall, H. S., Richmond, P., Nissen, M. D., et al. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31826327e4 · Cited by 59 · see citing works

Conservation of Meningococcal Antigens in the Genus Neisseria

Muzzi, A., Mora, M., Pizza, M., Rappuoli, R., & Donati, C. (2013) · mBio · doi:10.1128/mbio.00163-13 · Cited by 59 · see citing works

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

Vesikari, T., Østergaard, L. J., Díez‐Domingo, J., et al. (2015) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piv039 · Cited by 58 · see citing works

Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules

Johnson, S., Tan, L., van der Veen, S., Caesar, J. J. E., de Jorge, E. G., Harding, R., Bai, X., Exley, R. M., Ward, P. N., Ruivo, N., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002981 · Cited by 58 · see citing works

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial

Block, S. L., Szenborn, L., Daly, W., Jackowska, T., D’Agostino, D., Han, L., Dull, P. M., & Smolenov, I. V. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.001 · Cited by 57 · see citing works

Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine

Fagnocchi, L., Biolchi, A., Ferlicca, F., et al. (2012) · Infection and Immunity · doi:10.1128/iai.01085-12 · Cited by 57 · see citing works

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

Bambini, S., Chiara, M. D., Muzzi, A., et al. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00825-13 · Cited by 57 · see citing works

Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region

Soriano‐Gabarró, M., Wolter, J. M., Hogea, C. S., & Vyse, A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.89 · Cited by 53 · see citing works

The changing epidemiology of meningococcal disease in North America 1945–2010

Baccarini, C. I., Ternouth, A., Wieffer, H., & Vyse, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22302 · Cited by 52 · see citing works

Outer membrane protein (OMP) based vaccine for serogroup B

PILLAI, S., Howell, A. P., Alexander, K., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.056 · Cited by 51 · see citing works

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study

Perrett, K. P., McVernon, J., Richmond, P., Marshall, H. S., Nissen, M. D., August, A., Percell, S., Toneatto, D., & Nolan, T. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.103 · Cited by 51 · see citing works

Neisseria meningitidis Adhesin NadA Targets β1 Integrins

Nägele, V., Heesemann, J., Schielke, S., Soto, L. F. J., Kurzai, O., & Ackermann, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.188326 · Cited by 51 · see citing works

A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

Esposito, S., Prymula, R., Zuccotti, G., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29218 · Cited by 48 · see citing works

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease

Kaaijk, P., van Straaten, I., van de Waterbeemd, B., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.031 · Cited by 48 · see citing works

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries

Abad, R., Medina, V., Stella, M., Boccadifuoco, G., Comanducci, M., Bambini, S., Muzzi, A., & Vázquez, J. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150721 · Cited by 48 · see citing works

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine

Tzanakaki, G., Hong, E., Κεσανόπουλος, Κ., et al. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-111 · Cited by 47 · see citing works

Human monocytes/macrophages are a target ofNeisseria meningitidis Adhesin A(NadA)

Franzoso, S., Mazzon, C., Sztukowska, M. N., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1207810 · Cited by 46 · see citing works

Notes from the Field:Outbreak of Serogroup B Meningococcal Disease at a University — California, 2016

Biswas, H. H., Han, G. S., Wendorf, K. A., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6520a3 · Cited by 45 · see citing works

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

Vesikari, T., Wysocki, J., Beeslaar, J. F., Eiden, J., Jiang, Q. L., Jansen, K. U., Jones, T. R., Harris, S. L., O’Neill, R. E., York, L. J., et al. (2016) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piv064 · Cited by 41 · see citing works

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine

Senders, S. D., Bhuyan, P. K., Jiang, Q. L., et al. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001072 · Cited by 41 · see citing works

10th International Pathogenic Neisseria Conference

(1996) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1996.tb00208.x · Cited by 41 · see citing works

A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents

Muse, D. D., Christensen, S., Bhuyan, P. K., Absalon, J., Eiden, J., Jones, T. R., York, L. J., Jansen, K. U., O’Neill, R. E., Harris, S. L., et al. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001124 · Cited by 40 · see citing works

Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age

McQuaid, F., Snape, M. D., John, T. M., et al. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000327 · Cited by 39 · see citing works

A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups

Hoiseth, S. K., Murphy, E., Andrew, L., Vogel, U. F., Frosch, M., Hellenbrand, W., Abad, R., Vázquez, J. A., Borrow, R., Findlow, J., et al. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31829aa63b · Cited by 39 · see citing works

Structure of the C-terminal Domain of Neisseria Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against Neisseria meningitidis

Esposito, V., Musi, V., de Chiara, C., Veggi, D., Serruto, D., Scarselli, M., Kelly, G. P., Pizza, M., & Pastore, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289314 · Cited by 38 · see citing works

Neisseria meningitidisSerogroup X in Sub-Saharan Africa

Agnememel, A., Hong, E., Giorgini, D., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2204.150653 · Cited by 36 · see citing works

Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice

Rossi, R., Granoff, D. M., & Beernink, P. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.099 · Cited by 35 · see citing works

Molecular Epidemiology of Neisseria meningitidis Serogroup B in Brazil

de Filippis, I., de Lemos, A. P. S., Hostetler, J. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033016 · Cited by 35 · see citing works

A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants

Martinón‐Torres, F., Giménez‐Sánchez, F., Bernaola-Iturbe, E., Díez‐Domingo, J., Jiang, Q. L., & Perez, J. L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.049 · Cited by 34 · see citing works

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

McQuaid, F., Snape, M. D., John, T. M., et al. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141200 · Cited by 34 · see citing works

Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America1

Pollard, A. J., Ochnio, J., Ho, M., et al. (2004) · Emerging infectious diseases · doi:10.3201/eid1010.040335 · Cited by 34 · see citing works

Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion

Montanari, P., Bozza, G., Capecchi, B., et al. (2011) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01722.x · Cited by 33 · see citing works

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

Snape, M. D., Voysey, M., Finn, A. H. R., et al. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001056 · Cited by 33 · see citing works

Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine

Granoff, D. M., Costa, I., Konar, M., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv081 · Cited by 31 · see citing works

Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding

Granoff, D. M., Giuntini, S., Gowans, F. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88907 · Cited by 30 · see citing works

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults

Østergaard, L. J., Lucksinger, G. H., Absalon, J., Beeslaar, J. F., Eiden, J. J., Jansen, K. U., York, L. J., Quinn, A., Graversen, M. E., & Perez, J. L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.01.044 · Cited by 28 · see citing works

IFN-γ and R-848 Dependent Activation of Human Monocyte-Derived Dendritic Cells by Neisseria meningitidis Adhesin A

Mazzon, C., Baldani‐Guerra, B., Cecchini, P., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3904 · Cited by 26 · see citing works

Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets

Law, D. K. S., Lefebvre, B., Gilca, R., et al. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0469-6 · Cited by 25 · see citing works

Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa

Mothibeli, K. M., du Plessis, M., von Gottberg, A., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.072 · Cited by 25 · see citing works

A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB

Abad, R., Biolchi, A., Moschioni, M., et al. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00669-14 · Cited by 25 · see citing works

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children

Vesikari, T., Prymula, R., Merrall, E. L. C., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.079 · Cited by 23 · see citing works

Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB

Budroni, S., Kleinschmidt, A., Boucher, P. E., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.009 · Cited by 22 · see citing works

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

Ala’Aldeen, D. A. A., Flint, M., Oldfield, N. J., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.038 · Cited by 19 · see citing works

Neisseria meningitidisserogroup B bivalent factor H binding protein vaccine

Brendish, N. J., & Read, R. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1015997 · Cited by 19 · see citing works

Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness

POOLMAN, J. T., & Richmond, P. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1071670 · Cited by 18 · see citing works

Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial

Sáfadi, M. A. P., Martinón‐Torres, F., Weckx, L. Y., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.002 · Cited by 17 · see citing works

Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives

Signorelli, C., Chiesa, V., & Odone, A. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2015.56.3.484 · Cited by 15 · see citing works

Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?

Findlow, J. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1091131 · Cited by 15 · see citing works

Impact of Moderate Temperature Changes on Neisseria meningitidis Adhesion Phenotypes and Proteome

Lappann, M., Otto, A., Brauer, M., Becher, D., Vogel, U. F., & Johswich, K. O. (2016) · Infection and Immunity · doi:10.1128/iai.00584-16 · Cited by 12 · see citing works

4CMenB vaccine effectiveness: reasons for optimism

Basta, N. E., & Christensen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32061-x · Cited by 12 · see citing works

Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment

Wormsbecker, A. E., Wong, K., Jamieson, F. B., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.023 · Cited by 9 · see citing works

Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011

Boan, P., Metasan, N., Tempone, S., et al. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0686-x · Cited by 9 · see citing works

Meningococcal B Vaccine during a University Outbreak

Basta, N. E., Mahmoud, A. A. F., & Borrow, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610666 · Cited by 9 · see citing works

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes

Domnich, A., Gasparini, R., Amicizia, D., Boccadifuoco, G., Giuliani, M. M., & Panatto, D. (2015) · Journal of Immunology Research · doi:10.1155/2015/353461 · Cited by 8 · see citing works

Characterization of Invasive Neisseria meningitidis from Atlantic Canada, 2009 To 2013: With Special Reference to the Nonpolysaccharide Vaccine Targets (Pora, Factor H Binding Protein, Neisseria Heparin‐Binding Antigen and Neisseria Adhesin A)

Tsang, R. S. W., Law, D. K. S., Gad, R. R., et al. (2015) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2015/393659 · Cited by 7 · see citing works

MenB vaccine programme cuts cases of meningitis and septicaemia in infants

Wise, J. (2016) · BMJ · doi:10.1136/bmj.i4839 · Cited by 3 · see citing works

Global etiology of bacterial meningitis: A systematic review and meta-analysis.

Oordt-Speets, A. M., Bolijn, R., van Hoorn, R. C., Bhavsar, A., & Kyaw, M. H. (2018) · PloS One · doi:10.1371/journal.pone.0198772 · Cited by 288 · see citing works

Evidence for Indirect Nosocomial Transmission of Neisseria meningitidis Resulting in Two Cases of Invasive Meningococcal Disease

Elias, J., Health Office in the Rural District Office Wartburgkreis, Claus, H., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00613-06 · Cited by 14 · see citing works

Molecular Epidemiology of Neisseria meningitidis Isolates from an Outbreak of Meningococcal Disease among Men Who Have Sex with Men, Chicago, Illinois, 2003

Schmink, S. E., Watson, J. T., Coulson, G. B., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01190-07 · Cited by 31 · see citing works

Development of the epidemiological situation in invasive meningococcal disease in the Czech Republic caused by emerging Neisseria meningitidis clone ET-15/37.

Krízová, P., Musílek, M., & Kalmusová, J. (1997) · PubMed · Cited by 27 · see citing works

Necessity of Molecular Techniques To Distinguish between Neisseria meningitidis Strains Isolated from Patients with Meningococcal Disease and from Their Healthy Contacts

Vogel, U. F., Morelli, G., Zurth, K., et al. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.882-882.1999 · Cited by 2 · see citing works

Meningococcal Disease in the United States--1986

Pinner, R. W., Gellin, B. G., Bibb, W. F., et al. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.368 · Cited by 71 · see citing works